: iStockAnalyst.com Symbols Feed

7 Stock Picks For This Fine Market Manipulation Monday Morning

Mon, 21 Sep 2009 16:58:49 GMT

Speedus Corp. (SPDE) I took my loss quickly, when it was clear afterhours and premarket that the short sellers would try to knock it down quickly to scare away any and all momentum buyers…yes, it happens, took a $700+ loss and didn’t even consider buying or shorting it the rest of the day since I didn’t know what the shorts were doing and what was actually real…when there’s confusion, I just don’t trade it.[More...]

Hot Stocks Of The Day: PG, ARNA, HBAN, FSP, EL

Fri, 18 Sep 2009 18:42:30 GMT

US stocks were trading with gains on Friday as investors remained optimistic about economic recover amid the "quadruple witching," the simultaneous expiration of four types of futures and options contracts.[More...]

Extreme FDA Calendar Trades: 20 Stocks Under $5

Tue, 21 Jul 2009 12:47:00 GMT

Below are extreme trades among 20 companies with stock prices under $5 from the BioMedReports.com FDA Calendar, which includes 264 entries as of 7/20/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA fil (...)[More...]

NeuroSearch Experimental Obesity Drug To Begin Phase 3 Trials

Wed, 10 Jun 2009 12:07:09 GMT

As a trio of U.S. small-cap drug makers await crucial Phase 3 results later this year; NeuroSearch (CPH:NEUR) (PINK:NEUSF) is preparing to advance its own experimental weight loss drug to the final stage of clinical development following a successful End of Phase 2 meeting with the FDA which was announced earlier this week. Arena Pharma (NASDAQ:ARNA), Vivus (NASDAQ:VVUS), and Orexigen Therapeutics (NASDAQ:OREX) are all awaiting Phase 3 clinical trial data expected during 3Q09 for their experimen (...)[More...]

Pharmaceuticals & Biotech - Industry Outlook

Tue, 09 Jun 2009 12:05:35 GMT

The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x, including: Pfizer (PFE, 7.5x), Eli Lilly (LLY,[More...]

FDA Calendar Updates: MITI, KERX, GSK, DYAX, ARNA, PGNX

Mon, 08 Jun 2009 22:30:23 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of about 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response lett (...)[More...]

10 Extreme Trades On Pending Clinical Trial Results

Thu, 14 May 2009 15:37:15 GMT

As a follow-up to my recent article on nine extreme FDA trades of pending new product decisions among small and micro-cap companies, I have examined the BioMedReports.com Clinical Trial Calendar database to find companies with market caps below $250M which have pending Phase 2 or 3 clinical trial results expected before the end of 2009. Below is a sample of 10 stocks meeting this criteria from the database of 111 entries included in the BioMedReports.com Clinical Trial Calendar, which is in addi (...)[More...]

The Skinny On ARNA's Lorcaserin

Tue, 12 May 2009 16:46:50 GMT

Highlights include Arena Pharmaceuticals, Inc. (ARNA), Vivus, Inc. (VVUS), Orexigen Therapeutics, Inc. (OREX) Merck & Co., Inc. (MRK) and Johnson & Johnson (JNJ. Arena's Lorcaserin Approvable, But No Blockbuster On March 30, 2009, Arena Pharmaceuticals ([More...]

Arena (NASDAQ: ARNA) : A Risky Play – Drug-wise And Company-wise

Wed, 01 Apr 2009 14:05:59 GMT

Positive market news flow should normally lift market sentiment and stock prices related to that news. The lift is positively correlated to the strength of 'positivity' of the news. If the market signals thumbs-down then, in majority of the cases[More...]

Investing in Biotech Sector: Five Elements To Consider

Tue, 31 Mar 2009 18:46:00 GMT

When Arena Pharmaceuticals (Nasdaq: ARNA) released positive Phase III data on its obesity drug, Lorcaserin, many people expected shares to take off. After all, the company’s press release on Monday confirmed that the drug had proven to be safe and effective. But in a classic example of just how volatile and unpredictable the biotech sector can be, the stock slumped 28% instead. While the news was good on the surface, the problem was that Lorcaserin didn’t help patients lose 5% more of their body weight than placebo. The 5% figure is a guideline[More...]

3 new diet pills race to hit market

Thu, 22 Oct 2009 17:10:00 GMT

3 new diet pills race to hit market[More...]

Arena Pharmaceuticals Q2 Net Loss Narrows

Thu, 06 Aug 2009 14:52:00 GMT

Arena Pharmaceuticals has reported a net loss allocable to common stockholders of $38 million, or $0.48 per share, for the second quarter ended June 30, 2009, compared to a net loss allocable to common stockholders of $65.8 million, or $0.89 per share, in the second quarter of 2008.
For the first six months ended June 30, 2009, net loss allocable to common stockholders was $88.6 million, or $1.16 per share, compared to a net loss of $120.8 million, or $1.64 per share, in the first half of 2008.
Total revenues were $5.09 million, compared to $5.25 million in the same period of 2008.

[More...]

Why Clean Tech Is Taking Biotech's Shine

Tue, 07 Oct 2008 14:48:00 GMT

Nigel Beeley is a biopharma veteran.
He spent 25 years in research at such biotechnology companies as Amylin Pharmaceuticals (AMLN), Arena Pharmaceuticals (ARNA), and Senomyx (SNMX).
Beeley is not alone in looking beyond biopharmaceuticals for opportunities in clean tech, an industry comprised of companies focusing on alternative energy, recycling, conservation, and pollution reduction.

[More...]

PicksThatMove.Com Announces Investment Opinion on ARNA, MRVL, VVUS, NET and TSM

Mon, 26 Oct 2009 21:46:00 GMT

PicksThatMove is pleased to bring investors special situation stocks which have a high potential for price appreciation.
Arena Pharmaceuticals Inc. (NASDAQ: ARNA), $4.49, +$0.17, 4.92%, is enjoying a healthy price increase and a surge in shares traded into the afternoon.
Marvell Technology Group Ltd. (NASDAQ: MRVL), $14.99, +$0.41, 2.81%,a leading developer of storage, communications and consumer silicon solutions, has released an update on its third quarter outlook for fiscal 2010, ending October 31, 2009.

[More...]

BioMed Realty Trust Commemorates Five-Year Anniversary As a Public Company ; Ringing NYSE Closing Bell(R) Today; Provides Tenant Update

Thu, 06 Aug 2009 10:48:00 GMT

SAN DIEGO, Aug. 6 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR), The Leading Provider of Real Estate to the Life Science Industry(R), announced today that its board of directors and corporate officers will ring The Closing Bell(R) at the New York Stock Exchange on Thursday, August 6, 2009 at 4:00 p.m. Eastern Time to commemorate the fifth anniversary of the company's initial public offering.
BioMed's founders, Alan D. Gold, Chairman and Chief Executive Officer, and Gary A. Kreitzer, Executive Vice President, General Counsel and Director, will preside over the ringing of The Closing Bell(R).
"This is a great day for our team," said Mr. Gold.

[More...]

Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments

Mon, 03 Aug 2009 20:00:00 GMT

Arena Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2009.[More...]

Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference

Thu, 30 Jul 2009 11:59:00 GMT

Arena Pharmaceuticals, Inc. announced today that the company is scheduled to present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference on August 5, 2009 at 2:15 p.m. Eastern Time at the Millennium Broadway Hotel in New York City. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide an overview of the company, including its clinical development and research programs.[More...]

Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, August 3, 2009

Wed, 29 Jul 2009 12:02:00 GMT

Arena Pharmaceuticals, Inc. today announced it will report second quarter 2009 financial results after the NASDAQ Global Market closes on Monday, August 3, 2009. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, will host a conference call at 5:00 p.m. Eastern Time to discuss the financial results for the second quarter 2009 and to provide a business and financial update.[More...]

StockPreacher.com Issues Trading Outlook for Orexigen Therapeutics Inc.

Fri, 24 Jul 2009 10:45:00 GMT

StockPreacher.com announces an investment report featuring biopharmaceutical company Orexigen Therapeutics Inc. . The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.[More...]

Arena Pharmaceuticals Announces Public Offering of Common Stock

Tue, 07 Jul 2009 20:10:00 GMT

Arena Pharmaceuticals, Inc. announced today that it intends to offer shares of its common stock in a public offering. Piper Jaffray & Co. will be the sole underwriter for the offering. The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on November 25, 2008, which became effective on December 3, 2008. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission.[More...]

InvestorSoup.com Researches Wall Street Movers: Antigenics, Arena Pharma, Liz Claiborne, Powerwave Tech, Avis Budget Group, Unisys

Thu, 18 Jun 2009 15:05:00 GMT

Investment opinion and research company InvestorSoup.com announces the availability of free, detailed stock alerts on active stocks in today's news. Each stock alert highlights recent news, trading activity, technical analysis and relevant market research you need to know.[More...]

Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference

Thu, 18 Jun 2009 11:56:00 GMT

Arena Pharmaceuticals, Inc. announced today that the company is scheduled to present at the Piper Jaffray Fourth Annual Europe Conference on June 23, 2009 at 9:30 a.m. British Summer Time at the Andaz Hotel in London. Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief Scientific Officer, is scheduled to provide an overview of the company, including its clinical development and research programs.[More...]

Arena Pharmaceuticals to Receive $100 Million from Deerfield Management

Wed, 17 Jun 2009 11:59:00 GMT

Arena Pharmaceuticals, Inc. announced today that it has entered into an agreement with Deerfield Management, a leading healthcare investment organization and significant Arena stockholder, to provide Arena with $100 million in funding through a credit facility.[More...]